Key Takeaways
- • GenSight Biologics completed a EUR 1.1 million (gross) fundraising subscribed by existing shareholders Heights Capital and Invus, paid in full in cash, with net proceeds of approximately EUR 1.05 million.
- • The raise was priced at EUR 0.0708 per ABSA unit and EUR 0.0608 per Pre-Paid Unit, a 7% facial discount to the November 19, 2026 closing price of EUR 0.0761.
- • Proceeds fund operations until late March 2027, when first significant payments tied to the RECOVER Phase 3 trial fall due, and complement the October 2026 raise.
- • If all warrants were exercised, GenSight would receive additional gross proceeds of approximately EUR 925,669, though cash flow projections assume no exercise.
- • The issuance carries no lock-up commitments, and the new shares are expected to begin trading on Euronext Paris on November 24, 2026.
Summary
The offering was issued without preferential subscription rights and without a priority subscription period. It comprised 4,237,288 ordinary shares, 13,157,898 pre-funded warrants and 17,395,186 warrants. Investors could subscribe either to ABSA units (shares with attached investor warrants) at EUR 0.0708 per unit, or to Pre-Paid Units (pre-funded warrants with attached investor warrants) at EUR 0.0608 per unit. The Offered Investor Warrant exercise price is EUR 0.04565, and the pre-funded warrant exercise price is EUR 0.01 per share. The Company stated that the offering was decided on November 19, 2026 by the Chief Executive Officer under a delegation of authority from the board, which itself acted under the 19th resolution of the May 19, 2026 shareholders' meeting. The offering is not subject to a prospectus requirement under the EU Prospectus Regulation.
According to the company, the proceeds will finance operating activities and working capital, alongside revenues from early access programs, pending structural financing of the RECOVER Phase 3 trial. The raise, which supplements the October 2026 fundraising, covers the near-term funding need of up to EUR 2 million previously disclosed on September 29 and October 7, 2026. Funding is expected to last until late March 2027, subject to patient numbers under the French named patient early access program (AAC) being in line with estimates. CFO Jan Eryk Umiastowski said the company had completed on schedule the approximately EUR 2 million raise announced with its half-year results, and thanked Invus and Heights for their support since November 2024.
Dilution is material for existing holders. Post-issuance share capital will total 250,454,618 shares, rising to 272,310,109 if all warrants are exercised. A shareholder holding 1.00% pre-offering would fall to 0.98% non-diluted after the share issuance, and to 0.90% non-diluted after full exercise. The company's cash flow projections assume no warrant exercise. The Offered Shares are expected to be admitted to trading on Euronext Paris on November 24, 2026, and the company stated there are no lock-up commitments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.